PL2523661T3 - Inhibitory NKCC do leczenia autyzmu - Google Patents
Inhibitory NKCC do leczenia autyzmuInfo
- Publication number
- PL2523661T3 PL2523661T3 PL11700533T PL11700533T PL2523661T3 PL 2523661 T3 PL2523661 T3 PL 2523661T3 PL 11700533 T PL11700533 T PL 11700533T PL 11700533 T PL11700533 T PL 11700533T PL 2523661 T3 PL2523661 T3 PL 2523661T3
- Authority
- PL
- Poland
- Prior art keywords
- autism
- treatment
- nkcc
- inhibitors
- nkcc inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305047 | 2010-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2523661T3 true PL2523661T3 (pl) | 2017-09-29 |
Family
ID=42077420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11700533T PL2523661T3 (pl) | 2010-01-15 | 2011-01-13 | Inhibitory NKCC do leczenia autyzmu |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9415028B2 (pl) |
| EP (1) | EP2523661B1 (pl) |
| JP (1) | JP5914357B2 (pl) |
| CN (2) | CN102811716B (pl) |
| AU (1) | AU2011206574B2 (pl) |
| CA (1) | CA2786956C (pl) |
| CY (1) | CY1119167T1 (pl) |
| DK (1) | DK2523661T3 (pl) |
| ES (1) | ES2627914T3 (pl) |
| HR (1) | HRP20170836T1 (pl) |
| HU (1) | HUE034866T2 (pl) |
| LT (1) | LT2523661T (pl) |
| PL (1) | PL2523661T3 (pl) |
| PT (1) | PT2523661T (pl) |
| RS (1) | RS56080B1 (pl) |
| RU (1) | RU2583926C2 (pl) |
| SI (1) | SI2523661T1 (pl) |
| WO (1) | WO2011086126A1 (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| ES2732453T3 (es) | 2008-07-01 | 2019-11-22 | Curemark Llc | Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| CA3050530A1 (en) | 2009-01-06 | 2010-07-15 | Galenagen, Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| JP2012514604A (ja) | 2009-01-06 | 2012-06-28 | キュレロン リミテッド ライアビリティ カンパニー | 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法 |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| CN102811716B (zh) | 2010-01-15 | 2017-08-25 | 国立健康与医学研究所 | 用于治疗孤独症的化合物 |
| US20120252894A1 (en) * | 2011-04-01 | 2012-10-04 | Giniatullin Rashid | Compounds for alleviating pain and stress in fetus and newborn |
| MX362974B (es) | 2011-04-21 | 2019-02-28 | Curemark Llc | Compuestos para el tratamiento de alteraciones neuropsiquiatricas. |
| BR112014016557A8 (pt) * | 2012-01-03 | 2017-07-04 | Curemark Llc | métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| WO2013176774A1 (en) | 2012-05-25 | 2013-11-28 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| JP6382232B2 (ja) * | 2013-02-21 | 2018-08-29 | ユニバ−シティ オブ ロチェスタ− | 脳全体の傍血管経路を老廃物のクリアランス機能について評価するための方法、およびそれに基づいて神経変性障害を治療するための方法 |
| US9822368B2 (en) | 2013-12-20 | 2017-11-21 | Fondazione Istituto Italiano Di Tecnologia | Modulators of intracellular chloride concentration for treating down syndrome |
| WO2016025778A1 (en) * | 2014-08-15 | 2016-02-18 | The Johns Hopkins University | Compositions and methods for treating refractory seizures |
| NZ776366A (en) * | 2015-05-22 | 2023-02-24 | Univ Minnesota | Methods for treating autism spectrum disorder and associated symptoms |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| RU2633480C1 (ru) * | 2016-09-15 | 2017-10-12 | Александр Борисович Полетаев | Средство для стимуляции когнитивных функций при аутизме у детей |
| AU2018250823A1 (en) | 2017-04-10 | 2019-10-17 | Curemark, Llc | Compositions for treating addiction |
| EP3388520A1 (en) * | 2017-04-11 | 2018-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof |
| CA3072032A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
| CA3023014C (en) | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
| WO2019226643A1 (en) * | 2018-05-25 | 2019-11-28 | The Children's Medical Center Corporation | Methods for treating spinal cord injury |
| WO2020016160A1 (en) | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat neurological diseases |
| CN110684775A (zh) * | 2019-07-01 | 2020-01-14 | 上海海洋大学 | 一种中华绒螯蟹nkcc基因及其克隆方法和表达分析方法 |
| CA3147629A1 (en) | 2019-07-19 | 2021-01-28 | Finch Therapeutics Holdings Llc. | Methods and products for treatment of gastrointestinal disorders |
| US20220370390A1 (en) * | 2019-10-31 | 2022-11-24 | Neurochlore | Liquid oral formulation of bumetanide |
| BR112022010879A2 (pt) * | 2019-12-04 | 2022-10-18 | RESQ Pharmaceuticals LLC | Métodos e composições para tratamento de edema refratário a diuréticos orais |
| EP3881842A1 (en) * | 2020-03-19 | 2021-09-22 | Stalicla S.A. | Compositions for the treatment of autism spectrum disorder |
| WO2022006392A1 (en) * | 2020-07-01 | 2022-01-06 | Neuropro Therapeutics, Inc. | Novel pharmaceutical compositions |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985777A (en) | 1968-12-24 | 1976-10-12 | Lovens Kemiske Fabrik Produktionsaktieselskab | Sulphamyl-benzoic acid derivatives |
| US4247550A (en) | 1975-07-08 | 1981-01-27 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Compositions and methods for the treatment of hypertension or oedemas |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB2207129A (en) | 1987-07-13 | 1989-01-25 | Leo Pharm Prod Ltd | N-(1-carboxy-3-phenylpropyl)alanyl derivatives |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US8008283B2 (en) | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20070032410A1 (en) * | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| WO2001068836A2 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| JP2007504136A (ja) | 2003-08-28 | 2007-03-01 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法 |
| JP2008535836A (ja) * | 2005-04-07 | 2008-09-04 | ニューロセラピューティクス ファーマ エルエルシー | 不安障害の治療のための方法および組成物 |
| EP1968603A4 (en) | 2006-01-03 | 2013-01-16 | Algebra Inc | THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS |
| EP2065038A1 (en) * | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| CL2009000294A1 (es) | 2008-02-08 | 2009-10-23 | Shlorion Pharma Inc | Compuestos derivados de heterociclos aril metilideno; composicion farmaceutica que los comprende; y uso en el tratamiento del dolor neuropatico e inflamacion. |
| CN102036956A (zh) | 2008-03-21 | 2011-04-27 | 柯罗瑞恩制药有限公司 | 取代的吡咯烷和哌啶化合物、它们的衍生物、以及用于治疗疼痛的方法 |
| CN102341380A (zh) | 2009-01-22 | 2012-02-01 | 神经病治疗药物股份有限公司 | 布美他尼、呋塞米、吡咯他尼、佐塞米和托拉塞米类似物、组合物和使用方法 |
| CA2762680C (en) | 2009-05-21 | 2018-04-17 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
| CN102811716B (zh) | 2010-01-15 | 2017-08-25 | 国立健康与医学研究所 | 用于治疗孤独症的化合物 |
| CA2806664A1 (en) | 2010-07-26 | 2012-02-09 | Neurotherapeutics Pharma, Inc. | Arylsulfonamide derivatives, compositions, and methods of use |
-
2011
- 2011-01-13 CN CN201180014118.4A patent/CN102811716B/zh not_active Expired - Fee Related
- 2011-01-13 SI SI201131203T patent/SI2523661T1/sl unknown
- 2011-01-13 RU RU2012133067/15A patent/RU2583926C2/ru active
- 2011-01-13 HR HRP20170836TT patent/HRP20170836T1/hr unknown
- 2011-01-13 CN CN201710695535.9A patent/CN107595828A/zh active Pending
- 2011-01-13 CA CA2786956A patent/CA2786956C/en active Active
- 2011-01-13 JP JP2012548435A patent/JP5914357B2/ja not_active Expired - Fee Related
- 2011-01-13 EP EP11700533.0A patent/EP2523661B1/en active Active
- 2011-01-13 ES ES11700533.0T patent/ES2627914T3/es active Active
- 2011-01-13 PT PT117005330T patent/PT2523661T/pt unknown
- 2011-01-13 AU AU2011206574A patent/AU2011206574B2/en not_active Ceased
- 2011-01-13 LT LTEP11700533.0T patent/LT2523661T/lt unknown
- 2011-01-13 RS RS20170570A patent/RS56080B1/sr unknown
- 2011-01-13 PL PL11700533T patent/PL2523661T3/pl unknown
- 2011-01-13 US US13/522,372 patent/US9415028B2/en active Active
- 2011-01-13 DK DK11700533.0T patent/DK2523661T3/en active
- 2011-01-13 WO PCT/EP2011/050394 patent/WO2011086126A1/en not_active Ceased
- 2011-01-13 HU HUE11700533A patent/HUE034866T2/hu unknown
-
2013
- 2013-11-22 US US14/087,244 patent/US9592214B2/en not_active Expired - Fee Related
-
2017
- 2017-06-08 CY CY20171100608T patent/CY1119167T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20130022622A1 (en) | 2013-01-24 |
| JP5914357B2 (ja) | 2016-05-11 |
| US9592214B2 (en) | 2017-03-14 |
| CY1119167T1 (el) | 2018-02-14 |
| RU2012133067A (ru) | 2014-02-20 |
| US9415028B2 (en) | 2016-08-16 |
| DK2523661T3 (en) | 2017-07-03 |
| WO2011086126A1 (en) | 2011-07-21 |
| AU2011206574B2 (en) | 2015-01-22 |
| CA2786956A1 (en) | 2011-07-21 |
| EP2523661B1 (en) | 2017-05-10 |
| US20140080910A1 (en) | 2014-03-20 |
| SI2523661T1 (sl) | 2017-09-29 |
| RS56080B1 (sr) | 2017-10-31 |
| CN102811716B (zh) | 2017-08-25 |
| CA2786956C (en) | 2018-07-10 |
| PT2523661T (pt) | 2017-06-21 |
| HRP20170836T1 (hr) | 2017-09-08 |
| JP2013517251A (ja) | 2013-05-16 |
| AU2011206574A1 (en) | 2012-08-09 |
| ES2627914T3 (es) | 2017-08-01 |
| RU2583926C2 (ru) | 2016-05-10 |
| CN107595828A (zh) | 2018-01-19 |
| CN102811716A (zh) | 2012-12-05 |
| EP2523661A1 (en) | 2012-11-21 |
| LT2523661T (lt) | 2017-08-10 |
| HUE034866T2 (hu) | 2018-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2523661T (lt) | Nkcc inhibitoriai autizmo gydymui | |
| HRP20181185T1 (hr) | Inhibitori ibat za liječenje bolesti jetre | |
| IL225130A (en) | Devices for treating blood vessels defects | |
| ZA201304280B (en) | Treatment of jak2-mediated conditions | |
| IL231836A0 (en) | The vehicle for treating the siege | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| AP2013006680A0 (en) | Methods and compounds for treating paramyxoviridaevirus infections | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| IL228719A0 (en) | parp inhibitors for the treatment of cipn | |
| GB201018147D0 (en) | Method of treatment | |
| IL256026B (en) | Treatment methods | |
| GB201003920D0 (en) | Method of treatment | |
| PT2651251T (pt) | Composição para o tratamento de distúrbios metabólicos | |
| PL2608685T3 (pl) | Urządzenie do obróbki tytoniu | |
| PT2460509T (pt) | Composição para tratamento de verrugas | |
| GB201018149D0 (en) | Method of treatment | |
| GB201020045D0 (en) | Method for the treatment of biogas | |
| EP2585103A4 (en) | METHOD OF TREATMENT | |
| GB201020015D0 (en) | Method of treatment | |
| EG26997A (en) | Tube for treatment of syrngomylia | |
| GB201010671D0 (en) | Compounds for treatment of inflammation | |
| GB201005495D0 (en) | Compounds for treatment of inflammation | |
| GB201003917D0 (en) | Method of treatment | |
| GB201000318D0 (en) | Method of treatment | |
| GB201005071D0 (en) | Method of treatment |